Kyvernitakis I, Kostev K, Hars O, Albert U-S, Kalder M, Hadji P
a Department of Gynecological Endocrinology, Reproductive Medicine and Osteoporosis , Center for Gynecology and Obstetrics, Philipps-University of Marburg.
b IMS Health , Frankfurt.
Climacteric. 2015;18(6):826-34. doi: 10.3109/13697137.2015.1081164. Epub 2015 Oct 30.
Many women are reluctant to undergo estrogen replacement therapy (ERT) and discontinue the treatment within 12 months. The aim of this study was to investigate the persistence rates of ERT in hysterectomized women over the past decade, reflecting changes in the post-Women's Health Initiative (WHI) era.
We analyzed 8045 patients receiving ERT from 2004 to 2013 using the Disease Analyzer database.
After 12 months of follow-up, only 24.6% of patients receiving 1 mg and 24.5% of patients receiving 2 mg of oral ERT were still on treatment (p < 0.0001). The persistency rate of patients receiving <50 μg of transdermal ERT was 28.6% compared to 33.5% for patients receiving >50 μg within the 12 months of follow-up. ERT that began in 2007-2009 was associated with a higher discontinuation rate (hazard ratio 1.06, p = 0.0660) than ERT that began in 2010-2013 (hazard ratio 0.88, p = 0.0001).
Our results indicate low persistency rates in women on ERT irrespective of the dose as well as the route of administration. However, a decrease in discontinuation rates was found when comparing women in the early vs. late post WHI era.
许多女性不愿接受雌激素替代疗法（ERT），并在12个月内停止治疗。本研究的目的是调查过去十年中子宫切除术后女性ERT的持续率，反映妇女健康倡议（WHI）时代后的变化。
我们使用疾病分析仪数据库分析了2004年至2013年接受ERT的8045例患者。
随访12个月后，接受1毫克口服ERT的患者中只有24.6%仍在接受治疗，接受2毫克口服ERT的患者中这一比例为24.5%（p<0.0001）。在随访的12个月内，接受<50μg经皮ERT的患者持续率为28.6%，而接受>50μg经皮ERT的患者持续率为33.5%。2007 - 2009年开始的ERT与2010 - 2013年开始的ERT相比，停药率更高（风险比1.06，p = 0.0660）（风险比0.88，p = 0.0001）。
我们的结果表明，无论剂量和给药途径如何，接受ERT的女性持续率都较低。然而，比较WHI时代后期与早期的女性时，发现停药率有所下降。
